My research interest is in understanding the intricate role of immune cells in airway inflammation and remodeling associated with asthma. My research is focussed into:
Understanding the circadian mechanism of asthma- Asthma is very rhythmic. I will examine how clocks in the brain and lung contribute to the rhythmicity observed in asthma and define processes within the disease that are under the control of these clocks. This will lead to better management and treatment of patients with asthma, by revealing new drug targets and providing the timing information needed to use existing asthma treatments at the best time of the day.
Immunomodulation and anti-remodeling in chronic allergic airway disease using nanoparticles- One of my other research interests is in developing nanoparticle-based therapeutics by conjugating anti-fibrotic and amino acid molecules for preventing airway remodeling and airway inflammation.
Dr Amlan Chakraborty has an interest in unravelling the mechanisms by which innate immune cells play a role in airway inflammation and remodelling associated with chronic allergic airway disease (asthma). He has a masters degree by research followed by a PhD with Prof Cordelia Selomulya (UNSW, Sydney) and Prof Magdalena Plebanski (Translational Immunology, RMIT University, Melbourne) in developing novel immunomodulators to target airway inflammation associated with acute lung injury and asthma.
In 2019, he continued his role as a postdoctoral research associate with Prof. Selomulya investigating the interaction of peptide-conjugated nanoparticles in airway inflammation associated with asthma. In 2020, he was recruited as a postdoctoral research fellow in the Fibrosis Group, led by Prof. Chrishan Samuel at the Department of Pharmacology, Monash Biomedicine Discovery Institute Following that, Amlan got 2 industry-funded fellowships to investigate the role of induced pluripotent stem cells (iPSC) in pulmonary fibrosis and understanding the role of epithelial cell-repair and associated remodeling in chronic allergic airway disease (asthma).
Amlan has contributed to >20 publications, 7 patents (pending ratification) and has attracted $200K in commercial funding. Since completing his PhD in Pulmonary Immunology and Nanomedicine (2019, Monash University), his research focused on understanding airway remodeling and developing therapies using nanoparticles for pulmonary fibrosis and airway remodeling associated with asthma.
He has developed the anti-fibrotic hormone, serelaxin conjugated to nanoparticles for attenuation of airway inflammation and targeting airway remodeling. He also uses functionalized nanoparticles to understand the role of pulmonary myeloid cells associated with airway remodeling in asthma. Additionally, owing to the physicochemical properties of these particles, they can be traced inside the lung using a novel 3D ultra-short echo time Magnetic Resonance Imaging or using histochemical approaches.
Recently, Amlan has his research interest in understanding the circadian mechanisms in asthma.
Amlan has been involved in the "Pen-Pal program" to outreach, mentor, and engage young school children in science. He recently gained media popularity for his exciting research on developing inhalable nanoparticle immunomodulators to attenuate airway inflammation in the 4th annual industry showcase organised by BDI, Monash University, Melbourne.